As per the report published, the Antifungal Drugs Market size in North America is estimated at USD 4.97 billion in 2020. It is further projected to be growing at a CAGR of 3.7% and worth USD 5.96 billion by 2025. In the following years, the market is poised to grow significantly with the rising global population.
Antifungal drugs are commonly used to cure fungal infections due to unclean, unhygienic, and damp environments. Invasion of epithelial tissue by microscopic organisms leads to fungal infections. Systemic fungal infections are caused due to indigestion or inhalation of spores, leading to fungal pneumonia, and diseases like candidiasis, meningitis, mucormycosis, etc., are caused by opportunistic fungus. Although the majority of the fungal infections and diseases are commonly non-lethal, they are very uncomfortable to the host, and their common occurrence is responsible for the rising antifungal drugs market. Antifungal drugs work via various mechanisms such as by inhibiting cell wall formation, cell membrane disruption, and cell division.
The major factors driving the market are rising awareness of fungal infections with more and more cases of antifungal infections worldwide, an increase in government and corporate funding in the industry. Further, the growing public-private partnership in the pharmaceutical industry and the mounting popularity of over-the-counter antifungal drugs to cure dermal infections are responsible for the growth of the North America antifungal drugs market. Also, the rising population with weak immune systems because of cancer chemotherapy or acquired immunodeficiency syndrome, in whom the fungal infections occur more frequently than average, is driving the market in North America. The existing high penetration of conventional drugs used to treat common fungal infections is restraining market growth.
High drug costs are a challenge faced by the market. Increasing treatment effectiveness can help in overcoming it.
This research report on the North American Antifungal Drugs Market has been segmented and sub-segmented into the following categories:
By Drug Type:
By Therapeutic Indications:
By Application:
By Country:
Geographically, North America has commanded the largest share of the global antifungal drugs market. The United States antifungal drugs market contributes to the major share of the North America antifungal drugs market due to the presence of the leading companies. Canada's antifungal drug market is expected to grow fastest in the North American region.
Some of the major companies dominating the North American Antifungal drugs market are Alternaria, Pfizer, Novartis, Sanofi-Aventis, Merck & Co., Asperqillus, Kramer Laboratories, Bayer Healthcare, Enzon Pharmaceuticals, Glaxosmithkline Gilead, and Abbott Laboratories.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Drug Type
5.1.1 Echinocandins
5.1.2 Azoles
5.1.3 Polyenes
5.1.4 Allylamines
5.1.5 Others
5.2 By Therapeutic Indications
5.2.1 Aspergillosis
5.2.2 Dermatophytosis
5.2.3 Candidiasis
5.2.4 Others
5.3 By Application
5.3.1 Powders
5.3.2 Ointments
5.3.5 Drugs
5.3.4 Pastes
6. Geographical Analysis
6.1 Introduction
6.2 United States
6.3 Canada
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Alternaria
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Pfizer
8.3 Novartis
8.4 Sanofi-Aventis
8.5 Merck & Co.
8.6 Asperqillus
8.7 Kramer Laboratories
8.8 Bayer Healthcare
8.9 Enzon Pharmaceuticals
8.10 Glaxosmithkline Gilead
8.11 Abbott Laboratories
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
